Adalvo secures first EU approval for generic Liraglutide pre-filled pen, a type 2 diabetes treatment.
Adalvo Limited secures first EU generic approval for Liraglutide pre-filled pen, a bioequivalent version of Victoza® for type 2 diabetes treatment. The pre-filled pen, with global sales exceeding $4.8B in 2023, marks Adalvo's capability in offering diverse diabetes products. This approval reinforces Adalvo's position as a trusted leader in the pharmaceutical industry.
June 13, 2024
5 Articles